0.40Open0.40Pre Close0 Volume40 Open Interest185.00Strike Price0.00Turnover72.16%IV21.21%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier12DDays to Expiry0.40Extrinsic Value100Contract SizeAmericanOptions Type-0.0315Delta0.0023Gamma585.70Leverage Ratio-0.0845Theta-0.0024Rho-18.44Eff Leverage0.0305Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet